BCL2 and diffuse large B-cell lymphoma: In a preclinical study, the combination of copanlisib (PI3K inhibitor) and venetoclax extended the median survival of the DLBCL mice model bearing BCL2 translocation and DHL-BCL2-like genetic dysregulations [188].